Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs 10X Genomics Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 5.8× 10X Genomics Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and 10X Genomics Inc for 91 Days on average.
| TAK | TXG | |
|---|---|---|
Market Cap | $58.74B | $10.07B |
Volume | 3,110,994 | 5,657,286 |
Sector | Health | Health |
52-Week High | $19.05 | $97.74 |
52-Week Low | $13.23 | $11.48 |
Typical Hold Time | 1 Days | 91 Days |
Enterprise Value | $86.65B | $9.59B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
